Physician profile
Jason Aaron Salganick
NPI 1124125174
$1,614,349.00
in general payments reported to CMS, 2019-2025
84 companies · $182K in 2025
The $182K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239K · 2020: $128K · 2021: $276K · 2022: $322K · 2023: $255K · 2024: $211K · 2025: $182K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $463K · Travel and Lodging: $79K · Consulting Fee: $39K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $32K · Food and Beverage: $23K · Honoraria: $11K · Long Term Medical Supply Or Device Loan: $399 · Grant: $250 · Other payment types: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $462,815.97 |
| Travel and Lodging | $79,325.09 |
| Consulting Fee | $39,217.70 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $31,636.44 |
| Food and Beverage | $23,443.67 |
| Honoraria | $11,390.00 |
| Long Term Medical Supply Or Device Loan | $398.80 |
| Grant | $250.00 |
| Other payment types | $241.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $517,157.49 | 2019-2025 | Jakafi, Jakafi, Monjuvi |
| Taiho Oncology, INC. | $300,620.93 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $145,701.10 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Sobi, INC | $143,114.43 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $106,946.55 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Glaxosmithkline, LLC. | $68,987.70 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Daiichi Sankyo INC. | $65,303.12 | 2020-2025 | Enhertu, Vanflyta, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $54,297.32 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Genentech USA, INC. | $46,808.70 | 2019-2025 | Polivy, Tecentriq, Alecensa |
| Celgene Corporation | $46,786.88 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Cti Biopharma Corp. | $38,196.29 | 2022-2023 | Vonjo |
| Karyopharm Therapeutics INC. | $9,339.05 | 2020-2025 | Xpovio |
| Gilead Sciences, INC. | $5,710.27 | 2019-2025 | Trodelvy |
| Recordati_rare_diseases_inc. | $5,093.57 | 2024-2025 | Sylvant |
| Bayer Healthcare Pharmaceuticals INC. | $4,668.77 | 2019-2025 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,327.63 | 2019-2025 | |
| Geron Corporation | $3,317.98 | 2025 | Imetelstat, Rytelo |
| Foundation Medicine, INC. | $3,312.34 | 2019-2020 | |
| Abbvie INC. | $3,118.33 | 2020-2025 | Venclexta, Lupron Depot |
| Amgen INC. | $2,963.16 | 2019-2023 | Kyprolis, Lumakras |
| Array Biopharma INC | $2,890.92 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Tg Therapeutics, INC. | $2,797.92 | 2021-2022 | |
| Kite Pharma, INC. | $2,584.85 | 2019-2025 | Yescarta |
| Adc Therapeutics America, INC. | $2,559.22 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $2,528.64 | 2020-2025 | Rezlidhia, Gavreto, Tavalisse |
| Janssen Biotech, INC. | $2,519.41 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Exelixis INC. | $2,446.35 | 2019-2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $2,371.73 | 2019-2025 | Tazverik, Onivyde |
| Regeneron Healthcare Solutions, INC. | $2,233.73 | 2021-2024 | Libtayo |
| Genzyme Corporation | $2,184.36 | 2019-2025 | |
| Genmab U.S., INC. | $1,979.71 | 2023-2025 | Epkinly, Tivdak |
| Deciphera Pharmaceuticals INC. | $1,761.81 | 2020-2025 | Qinlock |
| Novartis Pharmaceuticals Corporation | $1,051.74 | 2019-2025 | |
| Astellas Pharma US INC | $910.70 | 2020-2025 | Xtandi, Padcev, Xospata |
| Alexion Pharmaceuticals, INC. | $863.93 | 2020-2025 | Ultomiris |
| Beigene USA, INC. | $802.36 | 2023-2024 | Brukinsa |
| Emd Serono, INC. | $782.47 | 2020-2025 | Tepmetko, Bavencio |
| Verastem, INC. | $550.18 | 2019-2020 | |
| Beigene, Ltd. | $525.00 | 2021 | |
| Seagen INC. | $453.56 | 2020-2023 | Padcev, Adcetris |
| Merck Sharp & Dohme LLC | $452.23 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $450.55 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $402.43 | 2020-2023 | Imbruvica, Epkinly |
| Eisai INC. | $255.45 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $217.08 | 2022-2025 | Clonoseq |
| Novocure Gmbh | $200.00 | 2022 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Puma Biotechnology, INC. | $169.61 | 2020-2024 | |
| Jazz Pharmaceuticals INC. | $161.81 | 2021-2025 | |
| Blueprint Medicines Corporation | $138.67 | 2020-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.44 | 2019-2021 | |
| Secura Bio, INC. | $129.15 | 2020-2021 | |
| Servier Pharmaceuticals LLC | $112.40 | 2024-2025 | |
| Springworks Therapeutics, INC. | $110.16 | 2024-2025 | Ogsiveo |
| Tersera Therapeutics LLC | $109.97 | 2023-2024 | Zoladex |
| Beone Medicines USA, INC. | $105.09 | 2025 | Tevimbra, Brukinsa |
| Cardinal Health 110 LLC | $100.00 | 2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Stemline Therapeutics INC. | $96.54 | 2023 | Orserdu |
| Kyowa Kirin, INC. | $86.51 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $85.26 | 2025 | Orgovyx |
| Mirati Therapeutics, INC. | $85.15 | 2023-2024 | Krazati |
| Clovis Oncology, INC. | $69.16 | 2020-2021 | |
| Pharmaessentia USA Corporation | $63.79 | 2023-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $57.09 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $52.34 | 2019 | |
| Coherus Oncology, INC. | $50.45 | 2025 | Loqtorzi |
| Genentech, INC. | $49.95 | 2021 | |
| Agios Pharmaceuticals, INC. | $43.53 | 2019 | |
| Spectrum Pharmaceuticals INC. | $42.60 | 2019 | |
| Morphosys, US INC. | $37.45 | 2021 | |
| Acrotech Biopharma INC. | $26.82 | 2025 | Beleodaq |
| Azurity Pharmaceuticals, INC. | $24.56 | 2025 | Danziten |
| Teva Pharmaceuticals USA, INC. | $24.55 | 2019 | |
| Dendreon Pharmaceuticals LLC | $23.67 | 2019 | |
| Csl Behring | $20.17 | 2022 | |
| Novocure INC. | $20.15 | 2022 | |
| Pharmacosmos Therapeutics INC. | $18.96 | 2025 | Monoferric |
| Sun Pharmaceutical Industries INC. | $18.59 | 2020 | |
| Macrogenics, INC. | $18.37 | 2022 | |
| Aurobindo Pharma USA, INC. | $16.56 | 2020 | |
| Myovant Sciences INC. | $14.03 | 2021 | |
| Tolmar, INC. | $13.51 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Salganick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.